Medicare Enrolled
Dr. Jeffrey O'Connor, M.D.
Urology Physician · Southfield, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. O'Connor from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. O'Connor?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. O'Connor
Dr. Jeffrey O'Connor is an urology physician in Southfield, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. O'Connor performed 8,348 Medicare services across 3,625 unique beneficiaries.
Between the years covered by Open Payments, Dr. O'Connor received a total of $4,910 from 53 pharmaceutical and/or device companies across 253 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. O'Connor is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 4% volume in MI
$4,910 industry payments
Medicare Practice Summary
Medicare Utilization ↗8,348
Medicare services
Top 4% in MI for urology physician
3,625
Unique beneficiaries
$50
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~417 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, degarelix, 1 mg | 3,520 | $3 | $8 |
| Automated urinalysis An automated laboratory test performed on a urine sample to analyze its chemical and physical properties. The procedure uses machinery to detect various substances and cells within the urine. |
850 | $2 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
740 | $92 | $235 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
594 | $8 | $41 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
347 | $64 | $92 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
330 | $185 | $575 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
314 | $65 | $160 |
| Complete ultrasound of retroperitoneum An ultrasound examination of the structures located behind the abdominal cavity. |
159 | $84 | $339 |
| Limited ultrasound of pelvis A focused ultrasound exam of the pelvic area to evaluate specific structures. This procedure provides images of the pelvis to assist in medical assessment. |
159 | $27 | $173 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
149 | $117 | $354 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
128 | $138 | $275 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 112 | $123 | $950 |
| Complex urodynamic pressure flow study A test that measures the pressure of urine flow in the bladder during voiding to evaluate how well the bladder and urethra are functioning. |
84 | $280 | $1,018 |
| Electronic assessment of bladder emptying A test that uses electronic monitoring to evaluate how well the bladder empties urine. |
71 | $6 | $180 |
| Abdominal device insertion with pressure and urine flow study A procedure involving the placement of a device into the abdomen, accompanied by a study to measure pressure and urine flow rate. |
66 | $154 | $422 |
| Simple insertion of temporary bladder tube A procedure to place a temporary tube into the bladder. This allows for the drainage of urine from the bladder. |
61 | $48 | $403 |
| Urethral dilation using endoscope A procedure to widen the urethra using a thin, lighted tube called an endoscope. This helps to open a narrowed urethral passage. |
53 | $258 | $910 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
52 | $11 | $48 |
| Non-needle muscle activity measurement of bladder and bowel openings This procedure measures and records the electrical activity of muscles at the bladder and bowel openings without using needles. |
48 | $26 | $430 |
| Injection, garamycin, gentamicin, up to 80 mg | 46 | $2 | $5 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
45 | $106 | $386 |
| Endoscopic destruction of bladder, urethra, or gland tissue A procedure that uses an endoscope to destroy tissue in the bladder, urethra, or surrounding glands. |
41 | $591 | $2,133 |
| Annual depression screening | 39 | $18 | $20 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
38 | $340 | $1,300 |
| Ureteral stent insertion via endoscope A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder. |
37 | $117 | $1,044 |
| Endoscopic destruction of bladder/urethra growth, less than 0.5 cm A procedure to remove abnormal tissue growths from the bladder or urethra using an endoscope. This specific code applies when the growths are smaller than 0.5 centimeters. |
31 | $611 | $2,228 |
| Ureteral stone crushing with endoscope A procedure to break up a stone in the ureter using an endoscope. The endoscope is inserted to locate and crush the stone. |
25 | $309 | $1,181 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
25 | $103 | $200 |
| Emergency department visit, moderate complexity An emergency department visit for an established or new patient involving a moderate level of medical decision making. |
24 | $100 | $263 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
23 | $179 | $760 |
| Ultrasound guidance for needle placement Use of ultrasound imaging to guide the precise placement of a needle during a medical procedure. |
23 | $46 | $172 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
22 | $93 | $314 |
| Ureteral stent insertion via cystoscopy A tube is placed into the ureter using an endoscope inserted through the bladder. |
21 | $73 | $614 |
| Endoscopic removal of urethral or bladder foreign body A procedure to remove a stone, stent, or other object from the urethra or bladder using an endoscope. The endoscope allows the provider to visualize and extract the item through the urinary tract. |
21 | $377 | $950 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
20 | $24 | $93 |
| Bladder stone removal, less than 2.5 cm A procedure to crush, fragment, and remove bladder stones that are smaller than 2.5 centimeters. |
17 | $705 | $1,959 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
13 | $97 | $129 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
55.6% medium
43.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,910
Total received (2018-2024)
Avg $701/year across 7 years
Top 34% in MI for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
53
Companies
253
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,910 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$676
2023
$847
2022
$882
2021
$763
2020
$359
2019
$637
2018
$746
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$113
Sumitomo Pharma America, Inc.
$80
Astellas Pharma US Inc
$66
Ferring Pharmaceuticals Inc.
$65
Myriad Genetic Laboratories, Inc.
$53
ABBVIE INC.
$52
Antares Pharma, Inc.
$42
PROGENICS PHARMACEUTICALS, INC.
$39
VERTEX PHARMACEUTICALS INCORPORATED
$29
Boston Scientific Corporation
$23
Olympus America Inc.
$22
AstraZeneca Pharmaceuticals LP
$20
PROCEPT BioRobotics Corporation
$20
180 Medical, Inc.
$18
Novartis Pharmaceuticals Corporation
$18
Janssen Biotech, Inc.
$16
Top 3 companies account for 38.4% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$752
Astellas Pharma US Inc
$641
Myriad Genetic Laboratories, Inc.
$303
Myovant Sciences Inc.
$228
Axonics, Inc.
$211
Coloplast Corp
$156
TOLMAR Pharmaceuticals, Inc.
$154
Janssen Pharmaceuticals, Inc
$141
Ferring Pharmaceuticals Inc.
$140
Sumitomo Pharma America, Inc.
$138
Antares Pharma, Inc.
$119
Janssen Biotech, Inc.
$119
Blue Earth Diagnostics Limited
$119
UROVANT SCIENCES INC
$114
Avadel Specialty Pharmaceuticals, LLC
$113
AstraZeneca Pharmaceuticals LP
$106
Endo Pharmaceuticals Inc.
$93
MEDIVATION FIELD SOLUTIONS LLC
$77
Amgen Inc.
$74
180 Medical, Inc.
$73
Bayer HealthCare Pharmaceuticals Inc.
$71
Clarus Therapeutics Inc.
$65
ABBVIE INC.
$65
Sun Pharmaceutical Industries Inc.
$57
COLOPLAST CORP
$45
AbbVie, Inc.
$44
Merck Sharp & Dohme LLC
$43
IsoRay, Inc
$41
PROGENICS PHARMACEUTICALS, INC.
$39
UroGen Pharma, Inc.
$39
Medtronic USA, Inc.
$38
Merck Sharp & Dohme Corporation
$36
Supernus Pharmaceuticals, Inc.
$36
Photocure Inc
$33
Dendreon Pharmaceuticals LLC
$29
VERTEX PHARMACEUTICALS INCORPORATED
$29
Tolmar, Inc.
$27
Allergan Inc.
$26
Bayer Healthcare Pharmaceuticals Inc.
$24
Boston Scientific Corporation
$23
GENZYME CORPORATION
$23
NeoTract Inc.
$22
Olympus America Inc.
$22
PROCEPT BioRobotics Corporation
$20
Medtronic, Inc.
$19
Rochester Medical Corporation
$19
Novartis Pharmaceuticals Corporation
$18
SRS Medical Systems, Inc.
$17
DENTSPLY IH AB
$16
Axonics Modulation Technologies, Inc.
$14
Allergan, Inc.
$14
Verity Pharmaceuticals Inc.
$14
UROGEN PHARMA, INC.
$13
Top 3 companies account for 34.5% of all-time payments
Associated products mentioned in payments ›
ADSTILADRIN · AMS 700 · AQUABEAM SYSTEM · AVEED · Axonics · Axonics r-SNM System · Axumin · BOTOX · BOTOX THERAPEUTIC · BRACHYTHERAPY SOURCE · Bulkamid · CYSVIEW · Cysview · ELIGARD · ERLEADA · Erleada · FIRMAGON · GEMTESA · INTERSTIM · INVOKANA · Isiris · JATENZO · JELMYTO · JEVTANA · KEYTRUDA · LYNPARZA · LoFric · Lupron · Lupron Depot · MYRBETRIQ · Myrbetriq · NOCDURNA · Noctiva · Nubeqa · ORGOVYX · PLUVICTO · PROLARIS · PROVENGE · PYLARIFY · Prolaris · Prolia · SPEEDICATH · SpeediCath · TITAN · TLANDO · TOVIAZ · Titan · Trelstar · UroCuff · UroLift · XIAFLEX · XTANDI · XYOSTED · Xtandi · YONSA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Urology physicians within 10 mi
177
Per 100K population
13.9
County median income
$95,296
Nearest hospital
ASCENSION PROVIDENCE HOSPITAL, SOUTHFIELD AND NOVI
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. O'Connor is a mixed practice specialist, with above-average Medicare volume (top 4% in MI), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. O'Connor experienced with injection, degarelix, 1 mg?
Based on Medicare claims data, Dr. O'Connor performed 3,520 injection, degarelix, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. O'Connor receive payments from pharmaceutical companies?
Yes. Dr. O'Connor received a total of $4,910 from 53 companies across 253 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. O'Connor's costs compare to other urology physicians in Southfield?
Dr. O'Connor's average Medicare payment per service is $50. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. O'Connor) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Southfield
Browse urology physicians in Southfield ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in MI
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in MI
Which MI urology physicians receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology